T-VEC-话题@MedSci

#T-VEC#

7篇内容 | 647人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1976849, encodeId=e65619e6849c4, content=<a href='/topic/show?id=7b3d1e0298a' target=_blank style='color:#2F92EE;'>#T-VEC#</a>, objectTitle=Cancer Sci：T-VEC治疗日本晚期黑色素瘤患者的安全性和有效性-I期研究, objectType=article, longId=736665, objectId=88b3e36665f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88b3e36665f7, replyNumber=0, likeNumber=30, createdTime=2022-08-28, rootId=0, userName=guihongzh, userId=66ec123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88b3e36665f7, moduleTitle=Cancer Sci：T-VEC治疗日本晚期黑色素瘤患者的安全性和有效性-I期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88b3e36665f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1976848, encodeId=f4c119e6848f7, content=<a href='/topic/show?id=7b3d1e0298a' target=_blank style='color:#2F92EE;'>#T-VEC#</a>, objectTitle=Nat Med：新辅助T-VEC联合手术对可切除的IIIB-IVM1a期黑色素瘤患者的疗效分析, objectType=article, longId=218211, objectId=4e7c218211d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e7c218211d8, replyNumber=0, likeNumber=36, createdTime=2021-11-29, rootId=0, userName=guihongzh, userId=66ec123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e7c218211d8, moduleTitle=Nat Med：新辅助T-VEC联合手术对可切除的IIIB-IVM1a期黑色素瘤患者的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e7c218211d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1976847, encodeId=d1ea19e68479f, content=<a href='/topic/show?id=7b3d1e0298a' target=_blank style='color:#2F92EE;'>#T-VEC#</a>, objectTitle=J Clin Oncol.：T-VEC提高晚期黑色素瘤患者的耐受反应率, objectType=article, longId=51538, objectId=a98d5153895, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a98d5153895, replyNumber=0, likeNumber=18, createdTime=2015-12-07, rootId=0, userName=guihongzh, userId=66ec123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a98d5153895, moduleTitle=J Clin Oncol.：T-VEC提高晚期黑色素瘤患者的耐受反应率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a98d5153895)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1976846, encodeId=a32b19e68465b, content=<a href='/topic/show?id=7b3d1e0298a' target=_blank style='color:#2F92EE;'>#T-VEC#</a>, objectTitle=JCO：溶瘤病毒T-VEC对晚期恶性黑色素瘤有持久的保护效应, objectType=article, longId=51280, objectId=2ffb51280fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ffb51280fc, replyNumber=0, likeNumber=31, createdTime=2015-08-14, rootId=0, userName=guihongzh, userId=66ec123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ffb51280fc, moduleTitle=JCO：溶瘤病毒T-VEC对晚期恶性黑色素瘤有持久的保护效应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ffb51280fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1976845, encodeId=b00d19e6845de, content=<a href='/topic/show?id=7b3d1e0298a' target=_blank style='color:#2F92EE;'>#T-VEC#</a>, objectTitle=癌症疫苗迎来转机：安进&默沙东合作开发癌症免疫鸡尾酒T-vec/Keytruda, objectType=article, longId=43905, objectId=b8314390543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8314390543, replyNumber=0, likeNumber=27, createdTime=2015-06-14, rootId=0, userName=guihongzh, userId=66ec123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8314390543, moduleTitle=癌症疫苗迎来转机：安进&默沙东合作开发癌症免疫鸡尾酒T-vec/Keytruda, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8314390543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1976843, encodeId=7fff19e684337, content=<a href='/topic/show?id=7b3d1e0298a' target=_blank style='color:#2F92EE;'>#T-VEC#</a>, objectTitle=安进溶瘤免疫疗法T-VecIII期触发系统性免疫, objectType=article, longId=31980, objectId=5f59319806e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f59319806e, replyNumber=0, likeNumber=23, createdTime=2014-03-27, rootId=0, userName=guihongzh, userId=66ec123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f59319806e, moduleTitle=安进溶瘤免疫疗法T-VecIII期触发系统性免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f59319806e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1976844, encodeId=227e19e684416, content=<a href='/topic/show?id=7b3d1e0298a' target=_blank style='color:#2F92EE;'>#T-VEC#</a>, objectTitle=安进黑色素瘤溶瘤免疫疗法T-Vec III期未改善总生存期, objectType=article, longId=33096, objectId=a01e33096d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a01e33096d2, replyNumber=0, likeNumber=34, createdTime=2014-06-18, rootId=0, userName=guihongzh, userId=66ec123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a01e33096d2, moduleTitle=安进黑色素瘤溶瘤免疫疗法T-Vec III期未改善总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a01e33096d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

T-VEC

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#T-VEC#

Cancer Sci：T-VEC治疗日本晚期黑色素瘤患者的安全性和有效性-I期研究

2022-08-28

guihongzh (审核中...)

前往app查看评论内容

#T-VEC#

Nat Med：新辅助T-VEC联合手术对可切除的IIIB-IVM1a期黑色素瘤患者的疗效分析

2021-11-29

guihongzh (审核中...)

前往app查看评论内容

#T-VEC#

J Clin Oncol.：T-VEC提高晚期黑色素瘤患者的耐受反应率

2015-12-07

guihongzh (审核中...)

前往app查看评论内容

#T-VEC#

JCO：溶瘤病毒T-VEC对晚期恶性黑色素瘤有持久的保护效应

2015-08-14

guihongzh (审核中...)

前往app查看评论内容

#T-VEC#

癌症疫苗迎来转机：安进&默沙东合作开发癌症免疫鸡尾酒T-vec/Keytruda

2015-06-14

guihongzh (审核中...)

前往app查看评论内容

#T-VEC#

安进溶瘤免疫疗法T-VecIII期触发系统性免疫

2014-03-27

guihongzh (审核中...)

前往app查看评论内容

#T-VEC#

安进黑色素瘤溶瘤免疫疗法T-Vec III期未改善总生存期

2014-06-18

科室
- - 订阅+
  - 更多科室
工具
服务